Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,283 | -62,293 | -27,029 | -41,307 | -43,241 |
| Depreciation Amortization | -1,240 | -1,056 | -743 | 197 | 699 |
| Accounts receivable | 38 | -49 | 562 | -81 | -507 |
| Accounts payable and accrued liabilities | -91 | 1,057 | -451 | 411 | -1,902 |
| Other Working Capital | 3,579 | -1,647 | -3,594 | 1,412 | -3,236 |
| Other Operating Activity | -19,800 | 38,564 | 7,320 | 12,345 | 11,472 |
| Operating Cash Flow | $-32,797 | $-25,424 | $-23,935 | $-27,023 | $-36,715 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -7,622 | -27,489 | 15,575 | -23,029 | 21,565 |
| PPE Investments | -174 | 5 | -34 | -247 | -5 |
| Investing Cash Flow | $-7,796 | $-27,484 | $15,541 | $-23,276 | $21,560 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 36,429 | 49,028 | 7,855 | N/A | 62,158 |
| Financing Cash Flow | $36,429 | $49,028 | $7,855 | $0 | $62,158 |
| Beginning Cash Position | 8,740 | 12,620 | 13,159 | 63,458 | 16,455 |
| End Cash Position | 4,576 | 8,740 | 12,620 | 13,159 | 63,458 |
| Net Cash Flow | $-4,164 | $-3,880 | $-539 | $-50,299 | $47,003 |
| Free Cash Flow | |||||
| Operating Cash Flow | -32,797 | -25,424 | -23,935 | -27,023 | -36,715 |
| Capital Expenditure | -174 | N/A | -34 | -269 | -5 |
| Free Cash Flow | -32,971 | -25,424 | -23,969 | -27,292 | -36,720 |